# Nuclide record f-18-florquinitau (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/f-18-florquinitau/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "f-18-florquinitau" ;
  schema:name "Florquinitau F-18"@en ;
  schema:alternateName "Tauklarify"@en, "florquinitau F 18 injection"@en, "Tauklarify" ;
  schema:description "A new PET scan tracer, approved by the FDA in August 2026, that shows tangled tau protein in the brain of adults with memory or thinking problems who are being assessed for Alzheimer's disease. It is read alongside other tests: a negative scan does not rule tau out and a positive one does not prove it."@en ;
  schema:url <https://nuclide.cc/drugs/f-18-florquinitau/> ;
  schema:dateModified "2026-09-27"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220496Orig1s000lbl.pdf>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220496>, <https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220496Orig1s000ltr.pdf> ;
  nuclide:status "approved" ;
  nuclide:tag "tau PET", "diagnostic", "neurology", "newly approved" ;
  nuclide:modality "PET tracer" ;
  nuclide:approval "US 2026: PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease, to identify patients with tau neurofibrillary tangle pathology" ;
  nuclide:related <https://nuclide.cc/indications/alzheimers-disease/>, <https://nuclide.cc/drugs/f-18-flortaucipir/>, <https://nuclide.cc/drugs/f-18-florbetapir/>, <https://nuclide.cc/drugs/f-18-flutemetamol/>, <https://nuclide.cc/drugs/f-18-florbetaben/>, <https://nuclide.cc/isotopes/f-18/> ;
  nuclide:companies <https://nuclide.cc/companies/lantheus/> .